We aimed to track the dynamics of IDO1 activity in stage III non-small cell lung cancer (NSCLC) patients who received first-line radiotherapy (RT) and explore its association with survival outcomes. This evidence concerns the gene IDO1 and non-small cell lung carcinoma.